Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 8 of 8 citing Scott: Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals.... (0.06 sec) 

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD …

- nih.gov
K Rajamani, PG Colman, LP Li, JD Best, M … - The Lancet, 2009 - Elsevier
In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study,
9795 patients aged 50–75 years with type 2 diabetes were randomly assigned by
computer-generated randomisation sequence to receive fenofibrate 200 mg per ...
Cited by 4 - Related articles - All 41 versions

Management of the statin-intolerant patient


WH Smiley, BV Khan, LS Sperling - Current Treatment Options in Cardiovascular Medicine, 2009 - Springer
The 3-hydroxy-3-methylglutaryl coenzyme A reduc- tase inhibitors (statins) have
a compelling track record. Large-scale clinical trials consistently have
demonstrated their effectiveness in reducing car- diovascular events and ...
Related articles - All 2 versions

Advances in Lipid Testing and Management in Diabetics


MM Vasudevan, CM Ballantyne - Endocrine Practice - AACE
Page 1. 1 Advances in Lipid Testing and Management in Diabetics Madhuri
M. Vasudevan, MD, MPH Christie M. Ballantyne, MD Center for ...
Related articles - All 2 versions

Exercise therapy in Type 2 diabetes


SFE Praet, LJC van Loon - Acta Diabetologica - Springer
Abstract Structured exercise is considered an important cornerstone to achieve
good glycemic control and improve cardiovascular risk profile in Type 2
diabetes. Current clinical guidelines acknowledge the therapeutic strength ...
Related articles - All 4 versions

Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia


AS Wierzbicki - Current Opinion in Cardiology, 2009 - journals.lww.com
Recent findings: Endpoint studies have been conducted with fibrates in coronary
heart disease (CHD) since 1971 and initial results were contradictory. Fibrates
later showed benefits in patients with low HDL-C and low LDL-C. The ...
Related articles - All 4 versions

Combination therapy of statins and fibrates in the management of cardiovascular risk


C Fiévet, B Staels - Current Opinion in Lipidology, 2009 - pdfs.journals.lww.com
Introduction An elevated LDL cholesterol (LDL-C) level is a major risk factor
for cardiovascular disease (CVD), and several randomized clinical trials have
shown that lowering LDL-C levels with statins results in a substantial ...
Related articles - All 4 versions

Advances in Lipid Testing and Management in Patients with Diabetes Mellitus


MM Vasudevan, CM Ballantyne - Endocrine Practice, 2009 - AACE
Submitted for publication July 7, 2009 Accepted for publication July 7, 2009
From the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart
and Vascular Center and Section of Atherosclerosis and Vascular Medicine, ...

[PDF] Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular …


CV Desouza, L Rentschler, V Fonseca - dovepress.com
© 2009 Desouza et al, publisher and licensee Dove Medical Press Ltd. This is an
Open Access article which permits unrestricted noncommercial use, provided the
original work is properly cited. ... Diabetes, Metabolic Syndrome and ...
Related articles - View as HTML - All 2 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google